Next Steps for Treatment of Ovarian Cancer

Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World Data

Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma

Vedolizumab and Standard Prophylaxis Proves Effective in Preventing GI aGVHD

Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT

Second Tisa-cel Infusion Demonstrates Short MRD-Negative Responses in Pediatric B-ALL

Nivolumab, Salvage Nivolumab, and Ipilimumab Improves TFS in Advanced RCC

Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World Data

Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma

Vedolizumab and Standard Prophylaxis Proves Effective in Preventing GI aGVHD

Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT

Second Tisa-cel Infusion Demonstrates Short MRD-Negative Responses in Pediatric B-ALL

Nivolumab, Salvage Nivolumab, and Ipilimumab Improves TFS in Advanced RCC

Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World Data

Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma

Vedolizumab and Standard Prophylaxis Proves Effective in Preventing GI aGVHD

Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT

Second Tisa-cel Infusion Demonstrates Short MRD-Negative Responses in Pediatric B-ALL

Nivolumab, Salvage Nivolumab, and Ipilimumab Improves TFS in Advanced RCC

Related Content

Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World Data

Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.

Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Vedolizumab and Standard Prophylaxis Proves Effective in Preventing GI aGVHD

Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.

Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT

The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.

Second Tisa-cel Infusion Demonstrates Short MRD-Negative Responses in Pediatric B-ALL

In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.